Hikal Limited Recommends Final Dividend for the Financial Year 2018-19 on Equity Share Capital; Reports Standalone and Consolidated Audited Earnings Results for the Quarter and Year Ended March 31, 2019
May 09, 2019 at 06:34 am EDT
Share
Hikal Limited announced that the Board has recommended final dividend for the financial year 2018-19 on equity share capital at 30% [INR 0.60 per equity share (nominal value INR 2 each)] at their meeting held on 9 May 2019, aggregating to dividend of 60% (INR 1.20 per equity share) {including Interim Dividend of INR 0.60 per share (30%) paid to the shareholders on 22 February 2019}, subject to the approval shareholders in the upcoming Annual General Meeting. Final Dividend, if approved by the shareholders at the upcoming AGM to be held on 1 August 2019, will be paid to the shareholders within 30 days of AGM date.
The company reported standalone and consolidated audited earnings results for the quarter and year ended March 31, 2019. For the quarter, on standalone basis, the company reported total revenue from operations of INR 4,575.0 million against INR 3,904.9 million a year ago. Total revenue was INR 4,575.5 million against INR 3,921.1 million a year ago. Profit for the period was INR 333.4 million against INR 253.4 million a year ago. Basic earnings per share was INR 2.70 against INR 2.06 a year ago.
For the year, on standalone basis, the company reported total revenue from operations of INR 15,896.1 million against INR 13,000.9 million a year ago. Total revenue was INR 15,918.7 million against INR 13,045.5 million a year ago. Profit for the period was INR 1,030.7 million against INR 772.3 million a year ago. Basic earnings per share was INR 8.36 against INR 6.26 a year ago.
For the year, on consolidated basis, the company reported total revenue from operations of INR 15,896.1 million against INR 13,000.9 million a year ago. Total revenue was INR 15,918.7 million against INR 13,045.5 million a year ago. Profit for the period was INR 1,030.6 million against INR 772.3 million a year ago. Basic earnings per share was INR 8.36 against INR 6.26 a year ago.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
Hikal Limited Recommends Final Dividend for the Financial Year 2018-19 on Equity Share Capital; Reports Standalone and Consolidated Audited Earnings Results for the Quarter and Year Ended March 31, 2019